Effects of Oral L-Carnitine on Liver Functions after Transarterial Chemoembolization in Intermediate-Stage HCC Patients

Table 5

Subgroup analysis in BCAA+ and BCAA− patients.

	Parameter (mean ± SD)	Pretreatment	After TACE
			1 week	4 weeks	12 weeks
BCAA+ ()	CP score	6.14 ± 1.04	6.43 ± 0.99	6.04 ± 1.03	6.24 ± 1.36
	S. albumin (g/dL)	3.18 ± 0.56	2.90 ± 0.48	3.25 ± 0.53	3.10 ± 0.49
	PT (%)	87.32 ± 18.99	88.50 ± 17.69	91.59 ± 18.19	88.13 ± 16.96
	T. bilirubin (mg/dL)	1.05 ± 0.59	1.10 ± 0.58	1.00 ± 0.56	1.22 ± 0.72
	ALT (IU/L)	37.07 ± 16.50	48.68 ± 24.95	35.89 ± 15.43	37.16 ± 11.05
	AST (IU/L)	52.04 ± 22.97	48.93 ± 24.65	50.79 ± 19.39	53.20 ± 18.43
	GGTP (IU/L)	69.89 ± 72.74	86.36 ± 100.41	89.26 ± 82.77	53.16 ± 36.19
BCAA− group ()	CP score	5.73 ± 0.93	5.90 ± 0.83	5.73 ± 0.76	6.05 ± 1.23
	S. albumin (g/dL)	3.41 ± 0.55	3.12 ± 0.56	3.38 ± 0.61	3.40 ± 0.60
	PT (%)	88.9 ± 17.2	88.8 ± 18.2	89.5 ± 16.5	89.9 ± 18.0
	T. bilirubin (mg/dL)	0.88 ± 0.38	0.99 ± 0.46	0.89 ± 0.43	1.02 ± 0.58
	ALT (IU/L)	37.86 ± 32.04	49.81 ± 32.60	38.00 ± 26.65	34.15 ± 20.24
	AST (IU/L)	57.36 ± 42.03	52.62 ± 34.73	60.27 ± 38.91	57.25 ± 46.66
	GGTP (IU/L)	66.59 ± 76.06	90.05 ± 127.71	100.82 ± 154.50	70.50 ± 82.04

SD: standard deviation; CP: Child-Pugh; S. albumin: serum albumin; PT: prothrombin time; T. bilirubin: total bilirubin; ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGTP: gamma-glutamyl transpeptidase; TACE: transarterial chemoembolization.
Significant difference compared with baseline value; significant difference compared with 1 week after TACE; significant difference compared with 4 weeks after TACE; ; ; .